Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8448074 | European Journal of Cancer | 2010 | 7 Pages |
Abstract
In our phase I study once daily administration of up to 1000Â mg of PTK/ZK in conjunction with concomitant temozolomide and radiotherapy was feasible and safe. Prolonged administration of this oral agent is manageable. The planned randomised phase II trial was discontinued right at its onset due to industry decision not to further develop this agent.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Alba A. Brandes, Roger Stupp, Peter Hau, Denis Lacombe, Thierry Gorlia, Alicia Tosoni, Renè O. Mirimanoff, Johan M. Kros, Martin J. van den Bent,